Indication

In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Medicine details

Medicine name:
encorafenib (Braftovi)
SMC ID:
SMC2238
Pharmaceutical company
Pierre Fabre Ltd
BNF chapter
Submission type
Resubmission
Status
Publication due date:
10 February 2020
SMC meeting date:
07 January 2020
Patient group submission deadline:
02 December 2019